Who is sponsoring NCT03547778?

NCT03547778 is sponsored by University of South Florida.

What drugs are being tested in NCT03547778?

Interventions in NCT03547778: Misoprostol 50 mcg pesssary, Placebos.

What condition does NCT03547778 study?

NCT03547778 studies Office Hysteroscopy and Endometrial Biopsy.

Is NCT03547778 still recruiting?

NCT03547778 is currently withdrawn. Last updated 18 June 2021.

Last reviewed 2021-06-18 · How we verify

NCT03547778

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

Withdrawn Phase 4 Last updated 18 June 2021

What this trial tests

Phase 4 trial testing Misoprostol 50 mcg pesssary in Office Hysteroscopy and Endometrial Biopsy. Withdrawn.

Timeline

1 September 2018

Primary endpoint
31 December 2019

25 March 2020

Quick facts

Lead sponsor	University of South Florida
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Start date	1 September 2018
Primary completion	31 December 2019
Estimated completion	25 March 2020
Sites	1 location across United States

Drugs / interventions tested

Misoprostol 50 mcg pesssary — full drug profile →
Placebos — full drug profile →

Conditions studied

Office Hysteroscopy and Endometrial Biopsy — all drugs for Office Hysteroscopy and Endometrial Biopsy →

Sponsor

University of South Florida

Who can join

Adults 18 to 70, female only, with Office Hysteroscopy and Endometrial Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We hypothesize that use of vaginal misoprostol will help in reducing the pain scores when used prior to concurrent office hysteroscopy and endometrial biopsy in a particular subgroup of women who are anticipated to require cervical dilatation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of South Florida trials

Trials by the same sponsor.

NCT07529366 — Pharmacist-Led Continuous Glucose Monitoring for Prediabetes · recruiting
NCT07342569 — The WeACT Program for Family Caregivers of People Living With Dementia · NA · not yet recruiting
NCT07502378 — Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic · Phase 4 · recruiting
NCT07241260 — Hydrate Heroes for Improving Brain Function & Mood · NA · not yet recruiting
NCT06377215 — Understanding Aided Speech Perception in Noise · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03547778 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of South Florida
Last refreshed: 18 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03547778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing